Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Frontiers in Immunology|August 13, 2021
HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 VaccineConcetta Ragone, Serena Meola, Pasqualina C Fiorillo, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 21, 2024
Cross-reactive CD8<sup>+</sup> T cell responses to tumor-associated antigens (TAAs) and homologous microbiota-derived antigens (MoAs)Beatrice Cavalluzzo, Marie Christine Viuff, Siri Amanda Tvingsholm, et al.
International Journal of Nanomedicine|August 1, 2023
Sorafenib-Loaded PLGA Carriers for Enhanced Drug Delivery and Cellular Uptake in Liver Cancer CellsTania Mariastella Caputo, Angela Maria Cusano, Sofia Principe, et al.
Journal of Translational Medicine|July 10, 2013
Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolateMaria Luisa Visciano, Maria Tagliamonte, Guillaume Stewart-Jones, et al.
The New Microbiologica|January 11, 2011
Quantitative HIV-1 proviral DNA detection: a multicentre analysisAnita De Rossi, Marisa Zanchetta, Francesca Vitone, et al.
Cancer Research|February 29, 2020
Exploiting Preexisting Immunity to Enhance Oncolytic Cancer ImmunotherapySiri Tähtinen, Sara Feola, Cristian Capasso, et al.
Frontiers in Immunology|November 8, 2021
MHC-Optimized Peptide Scaffold for Improved Antigen Presentation and Anti-Tumor ResponseMaria Tagliamonte, Angela Mauriello, Beatrice Cavalluzzo, et al.
Journal for Immunotherapy of Cancer|February 23, 2022
Neoantigens as potential vaccines in hepatocellular carcinomaDavid Repáraz, Marta Ruiz, Diana Llopiz, et al.
Cell Host & Microbe|October 31, 2024
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patientsAngeli D G Macandog, Carlotta Catozzi, Mariaelena Capone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2022
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular CarcinomaMarkus W Löffler, Stefania Gori, Francesco Izzo, et al.
Pageof 7